Related Experiment Video
Updated: Jun 29, 2026
Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
Efficacy and Safety of Etrasimod in Moderate-To-Severe Ulcerative Colitis: A GRADE-Based Systematic Review and
Anurag Jha1, Nirmal Paudel2, Khawaja Arham Jawaid3
1King Edward Medical University, Lahore, Pakistan.
Background:
Etrasimod is an oral sphingosine-1-phosphate receptor modulator evaluated for induction and maintenance therapy in moderately to severely active ulcerative colitis (UC). This meta-analysis aimed to assess the efficacy and safety of etrasimod in adults with active UC.
Objectives:
To assess the efficacy and safety of etrasimod as induction and maintenance therapy in adults with moderately to severely active UC.
Methods:
A systematic review and meta-analysis of randomized controlled trials (RCTs) comparing etrasimod with placebo in adults (≥18 years) with moderately to severely active UC was conducted by searching PubMed, Embase, Scopus, Cochrane CENTRAL, and ClinicalTrials.gov through November 2025. Dichotomous outcomes were pooled as risk ratios (RRs) with 95% confidence intervals (CIs) using random-effects models; heterogeneity was assessed with I2 and χ2 statistics. Analyses were performed with RevMan 5.4.
Results:
Four RCTs, including 1239 patients (etrasimod = 826; placebo = 413) were analyzed. At 12 weeks, etrasimod significantly improved clinical remission (RR = 2.92, 95% CI 1.71-4.98; I2 = 57%), clinical response (RR = 1.71, 95% CI 1.46-2.02; I2 = 19%), endoscopic improvement (RR = 1.72, 95% CI 1.30-2.27; I2 = 36%), and mucosal healing (RR = 3.11, 95% CI 1.72-5.62; I2 = 54%). Beyond 40 weeks, etrasimod increased clinical remission (RR = 4.28, 95% CI 2.72-6.73; I2 = 0%), clinical response (RR = 2.20, 95% CI 1.74-2.78; I2 = 0%), endoscopic improvement (RR = 3.51, 95% CI 2.36-5.23; I2 = 0%), mucosal healing (RR = 6.93, 95% CI 3.61-13.33; I2 = 0%), and steroid-free remission (RR = 4.28, 95% CI 2.72-6.73; I2 = 0%). Any treatment-emergent adverse event was slightly higher with etrasimod (RR = 1.15, 95% CI 1.04-1.28; I2 = 0%), while serious adverse events (RR = 0.79, 95% CI 0.39-1.61; I2 = 38%) and discontinuations due to adverse events (RR = 2.17, 95% CI 0.54-8.67; I2 = 50%) did not differ significantly.
Conclusion And Relevance:
Etrasimod is effective in inducing and maintaining clinical and endoscopic remission in moderate-to-severe UC, with an acceptable safety profile.
More Related Videos
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
05:41Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
Published on: April 6, 2022
Related Concept Videos
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:21Drugs for Treatment of Constipation-Predominant IBS
01:29Drugs for Treatment of Ulcerative Colitis in IBD
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...